https://scholars.lib.ntu.edu.tw/handle/123456789/551066
標題: | Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection | 作者: | CHEN-HUA LIU TUNG-HUNG SU CHUN-JEN LIU CHUN-MING HONG HUNG-CHIH YANG TAI-CHUNG TSENG PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2019 | 出版社: | Blackwell Publishing | 卷: | 34 | 期: | 9 | 起(迄)頁: | 1620-1625 | 來源出版物: | Journal of Gastroenterology and Hepatology (Australia) | 摘要: | Background and Aim: Data regarding the comparative effectiveness and safety of sofosbuvir (SOF) in combination with ribavirin (RBV), daclatasvir (DCV), or ledipasvir (LDV) for hepatitis C virus genotype 2 (HCV-2) patients were limited. We aimed to evaluate the performance of these regimens in Taiwan. Methods: One hundred eighty-seven HCV-2 patients with compensated liver diseases receiving SOF in combination with RBV (n?=?82), DCV (n?=?66), or LDV (n?=?39) for 12?weeks were retrospectively enrolled. The effectiveness was determined by sustained virologic response 12?weeks off therapy (SVR12). The patient characteristics potentially related to SVR12 were compared. The safety profiles and laboratory abnormalities were assessed. Results: The SVR12 rates were 93.9% (95% confidence interval [CI]: 86.5–97.4%), 98.5% (95% CI: 91.9–99.7%), and 100% (95% CI: 91.0–100%) in patients receiving SOF combined with RBV, DCV, and LDV, respectively. All patients tolerated treatment well. The stratified SVR12 rates were comparable regardless of baseline characteristics or week 4 viral decline among these regimens. Six (3.2%) patients had serious adverse events which were not related to treatment. The rates of fatigue, pruritus, and anemia tended to be higher in patients receiving RBV (22.0%, 19.5%, and 8.5%) combination than those receiving DCV (10.6%, 6.1%, and 1.5%) or LDV (10.3%, 5.1%, and 0%) combination. Conclusions: Sofosbuvir in combination with RBV, DCV, or LDV for 12?weeks is effective and well-tolerated for HCV-2 patients. Compared with DCV or LDV combination, the risks of fatigue, pruritus, and anemia are higher in patients receiving RBV combination. ? 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061794273&doi=10.1111%2fjgh.14615&partnerID=40&md5=e8dfb374a55eb3588d46475edc4784ad https://scholars.lib.ntu.edu.tw/handle/123456789/551066 |
ISSN: | 0815-9319 | DOI: | 10.1111/jgh.14615 | SDG/關鍵字: | antivirus agent; benzimidazole derivative; daclatasvir; fluorene derivative; imidazole derivative; ledipasvir, sofosbuvir drug combination; ribavirin; sofosbuvir; uridine phosphate; aged; chronic hepatitis C; comparative effectiveness; comparative study; drug effect; female; genetics; genotype; Hepacivirus; human; male; middle aged; retrospective study; sustained virologic response; Taiwan; time factor; treatment outcome; virology; Aged; Antiviral Agents; Benzimidazoles; Comparative Effectiveness Research; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Time Factors; Treatment Outcome; Uridine Monophosphate |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。